Related Experiment Video
Updated: Sep 26, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Anticoagulation in acute cardiac care in patients with chronic kidney disease
Donal Reddan1, Lynda A Szczech, Susan O'Shea
1Duke Institute of Renal Outcomes Research and Health Policy, Duke University Medical Center, Durham, NC 27710, USA. redda001@mc.duke.edu
Insights
Direct thrombin inhibitors offer a promising alternative to heparin for patients with chronic kidney disease (CKD) and cardiovascular disease, especially those at high bleeding risk. Dose adjustments are crucial for those with advanced renal insufficiency.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Growing prevalence of patients with coexisting chronic kidney disease (CKD) and cardiovascular disease presents treatment challenges.
- Limited pharmacokinetic and clinical trial data exist for managing these complex patient populations.
- Cardiovascular disease risk is significantly elevated in patients with CKD.
Purpose of the Study:
- To review the cardiovascular disease risks associated with CKD.
- To evaluate the use of anticoagulation for acute cardiovascular events in CKD patients.
- To assess the role and clinical efficacy of direct thrombin inhibitors, specifically bivalirudin, in patients with renal disease and acute coronary syndromes.
Main Methods:
- Literature review focusing on cardiovascular disease in CKD.
- Analysis of clinical trial data and pharmacokinetic studies related to anticoagulation in renal insufficiency.
- Evaluation of direct thrombin inhibitors (bivalirudin, argatroban) as alternatives to heparin.
Main Results:
- Direct thrombin inhibitors show potential as alternatives to heparin in patients with renal insufficiency and increased bleeding risk.
- Bivalirudin's clinical efficacy in acute coronary syndromes within this patient group was specifically examined.
- Heparin use in CKD patients is associated with increased bleeding risk.
Conclusions:
- Direct thrombin inhibitors, including bivalirudin and argatroban, are promising anticoagulation options for patients with renal insufficiency.
- These agents may offer a safer profile compared to heparin in CKD patients at high risk of bleeding.
- Dose modification of direct thrombin inhibitors is essential for patients with advanced renal insufficiency to manage altered drug excretion.
Abstract:
The number of patients with coexisting chronic kidney disease (CKD) and cardiovascular disease is growing rapidly. Treatment of these patients is challenging, primarily because of a lack of pharmacokinetic and clinical trial data associated with these combined disease entities. In this report, we discuss the cardiovascular disease risk associated with CKD and review the use of anticoagulation for acute cardiovascular disease in patients with CKD. We evaluate the potential role of direct thrombin inhibitors in patients with renal disease who have acute coronary syndromes, with particular focus on the clinical efficacy of bivalirudin. We conclude that direct thrombin inhibitors, including bivalirudin and argatroban, may be promising alternatives to heparin in patients who have renal insufficiency and are therefore at an increased risk for bleeding. In the treatment of patients with advanced renal insufficiency and cardiovascular disease, however, these agents should be used with dose modification to account for altered excretion.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Cardiac Catheterization I: Pre-Procedure Overview
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury VI: Nursing Management